BC1618
BC1618, an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling (via preventing activated pAmpkα from Fbxo48-mediated degradation) . BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity[1].
Product Specifications
CAS Number
[2222094-18-8]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
AMPK; E1/E2/E3 Enzyme; Mitophagy
Type
Reference compound
Related Pathways
Autophagy; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bc1618.html
Concentration
10mM
Purity
99.74
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(COC1=CC=C(C(F)(F)F)C=C1)CN(CC2=CC=CC=C2)CC3=CC=CC=C3
Molecular Formula
C24H24F3NO2
Molecular Weight
415.45
Precautions
H302, H315, H319, H335
References & Citations
[1]Yuan Liu, et al. A Fbxo48 inhibitor prevents pAMPKα degradation and ameliorates insulin resistance. Nat Chem Biol. 2021 Mar;17 (3) :298-306.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CCT6B (T-complex Protein 1 Subunit zeta-2, TCP-1-zeta-2, CCT-zeta-2, CCT-zeta-like, TCP-1-zeta-like, Testis-specific Tcp20, Testis-specific Protein TSA303) (MaxLight 750) discontinued
Lentiviral human KCNJ9 shRNA (UAS) - Lentiviral human KCNJ9 shRNA (UAS, iRFP) (100)
